Pharmacy benefit managers (PBMs) are being targeted yet again by the government. James Comer (R-Ky), House Committee on Oversight and Accountability chairman, launched an investigation Wednesday into PBMs and their “tactics that are harming…
Continue Reading
Sun Pharma probes cyber breachIndian pharma giant Sun Pharmaceutical Industries has reported an “information security incident,” according to PTI.
The news report noted that the company has already reported the incident to the authorities and has…
The pain drug market has many products, but there’s still a need for pills with better properties, such as avoiding addiction. Eli Lilly sees potential in the non-opioid pain drug research from Confo Therapeutics…
Continue Reading
The biggest threats employers are facing right now include high-cost pharmacy claims, medical inflation and million dollar treatments being approved by the Food and Drug Administration, a Wednesday survey found.
The report was conducted by…
MorphoSys, a company whose research has yielded programs placed with big pharmaceutical companies and upstart biotechs, is stopping all preclinical work to focus on cancer, particularly a late-stage drug candidate it acquired in a…
Continue Reading
Multinational pharmaceutical and biotech company Pfizer and AI-powered data company Tempus announced a multi-year strategic alliance to utilize AI and machine learning to inform drug discovery and development in oncology. Pfizer will leverage Tempus’ library…
Continue Reading
What You Should Know:– C2i Genomics, a cancer intelligence company, today announced a collaboration with Riken Genesis Co., Ltd. (RG), a company specializing in providing the service of personalized medicine based on contract analysis…
Continue ReadingWhat You Should Know:[embedded content]– Eli Lilly and Company today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less…
Continue Reading
As a health economist, researcher in evidence-based medicine, and consultant to biopharma executives, I am no stranger to data. We all want more of it, to make sense of it, and to use it…
Continue Reading
GoodRx reported falling revenue for the fourth quarter, but its stock rallied early Wednesday after beating earnings expectations. The company, best known for its drug cost transparency tools, reported $184.1 million in revenue for Q4…
Continue Reading
